Biotechnology: 219 U.S.-Listed Stocks by Market Cap
EquiReason covers 219 U.S.-listed companies in the Biotechnology industry (Healthcare sector), with a combined market cap of $994.3B. The largest by market cap: Vertex Pharmaceuticals Incorporated (VRTX, $132.8B), Regeneron Pharmaceuticals, Inc. (REGN, $82.9B), Moderna, Inc. (MRNA, $79.9B), Revolution Medicines, Inc. (RVMD, $40.1B), Royalty Pharma plc (RPRX, $36.7B).
Sector and industry classification and market cap at the latest close: EquiReason company data · financial statements on each company's page come from its SEC filings
Companies by market cap
| # | Company | Market cap |
|---|---|---|
| 1 | VRTX Vertex Pharmaceuticals Incorporated | $132.8B |
| 2 | REGN Regeneron Pharmaceuticals, Inc. | $82.9B |
| 3 | MRNA Moderna, Inc. | $79.9B |
| 4 | RVMD Revolution Medicines, Inc. | $40.1B |
| 5 | RPRX Royalty Pharma plc | $36.7B |
| 6 | ALNY Alnylam Pharmaceuticals, Inc. | $30.0B |
| 7 | ROIV Roivant Sciences Ltd. | $26.4B |
| 8 | INCY Incyte Corporation | $23.5B |
| 9 | INSM Insmed Incorporated | $20.4B |
| 10 | EXEL Exelixis, Inc. | $16.0B |
| 11 | ASND Ascendis Pharma A/S | $15.1B |
| 12 | HALO Halozyme Therapeutics, Inc. | $14.3B |
| 13 | JAZZ Jazz Pharmaceuticals plc | $13.9B |
| 14 | BBIO BridgeBio Pharma, Inc. | $13.4B |
| 15 | SMMT Summit Therapeutics Inc. | $12.3B |
| 16 | TECH Bio-Techne Corporation | $11.4B |
| 17 | BMRN BioMarin Pharmaceutical Inc. | $10.8B |
| 18 | MDGL Madrigal Pharmaceuticals, Inc. | $10.0B |
| 19 | CORT Corcept Therapeutics Incorporated | $9.3B |
| 20 | KRYS Krystal Biotech, Inc. | $9.2B |
| 21 | KYMR Kymera Therapeutics, Inc. | $9.2B |
| 22 | CAI Caris Life Sciences, Inc. | $9.0B |
| 23 | PCVX Vaxcyte, Inc. | $9.0B |
| 24 | PTGX Protagonist Therapeutics, Inc. | $9.0B |
| 25 | IBRX ImmunityBio, Inc. | $8.7B |
| 26 | CYTK Cytokinetics, Incorporated | $8.5B |
| 27 | TGTX TG Therapeutics, Inc. | $8.3B |
| 28 | ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B |
| 29 | SYRE Spyre Therapeutics, Inc. | $8.0B |
| 30 | AXSM Axsome Therapeutics, Inc. | $7.6B |
| 31 | IONS Ionis Pharmaceuticals, Inc. | $7.1B |
| 32 | PRAX Praxis Precision Medicines, Inc. | $7.1B |
| 33 | IOVA Iovance Biotherapeutics, Inc. | $6.4B |
| 34 | RYTM Rhythm Pharmaceuticals, Inc. | $6.1B |
| 35 | LGND Ligand Pharmaceuticals Incorporated | $6.1B |
| 36 | IMVT Immunovant, Inc. | $5.9B |
| 37 | MANE Veradermics, Incorporated | $5.8B |
| 38 | KOD Kodiak Sciences Inc. | $5.5B |
| 39 | CGON CG Oncology, Inc. | $5.5B |
| 40 | COGT Cogent Biosciences, Inc. | $5.4B |
| 41 | ORKA Oruka Therapeutics, Inc. | $5.3B |
| 42 | MIRM Mirum Pharmaceuticals, Inc. | $5.2B |
| 43 | PTCT PTC Therapeutics, Inc. | $5.1B |
| 44 | SRRK Scholar Rock Holding Corporation | $5.1B |
| 45 | ERAS Erasca, Inc. | $5.0B |
| 46 | DFTX Definium Therapeutics, Inc. | $4.8B |
| 47 | CRSP CRISPR Therapeutics AG | $4.8B |
| 48 | TVTX Travere Therapeutics, Inc. | $4.7B |
| 49 | GOSS Gossamer Bio, Inc. | $4.6B |
| 50 | DNTH Dianthus Therapeutics, Inc. | $4.3B |
| 51 | EWTX Edgewise Therapeutics, Inc. | $4.3B |
| 52 | RLAY Relay Therapeutics, Inc. | $4.0B |
| 53 | TNGX Tango Therapeutics, Inc. | $3.9B |
| 54 | ARQT Arcutis Biotherapeutics, Inc. | $3.9B |
| 55 | XENE Xenon Pharmaceuticals Inc. | $3.4B |
| 56 | ACAD ACADIA Pharmaceuticals Inc. | $3.4B |
| 57 | IDYA IDEAYA Biosciences, Inc. | $3.3B |
| 58 | CELC Celcuity Inc. | $3.2B |
| 59 | ELVN Enliven Therapeutics, Inc. | $3.0B |
| 60 | TARS Tarsus Pharmaceuticals, Inc. | $3.0B |
| 61 | DNLI Denali Therapeutics Inc. | $2.9B |
| 62 | DYN Dyne Therapeutics, Inc. | $2.9B |
| 63 | IRON Disc Medicine, Inc. | $2.9B |
| 64 | VKTX Viking Therapeutics, Inc. | $2.8B |
| 65 | NRIX Nurix Therapeutics, Inc. | $2.8B |
| 66 | VRDN Viridian Therapeutics, Inc. | $2.5B |
| 67 | BEAM Beam Therapeutics Inc. | $2.5B |
| 68 | ADMA ADMA Biologics, Inc. | $2.4B |
| 69 | RCUS Arcus Biosciences, Inc. | $2.4B |
| 70 | MBX MBX Biosciences, Inc. | $2.3B |
| 71 | SLS SELLAS Life Sciences Group, Inc. | $2.3B |
| 72 | CLDX Celldex Therapeutics, Inc. | $2.3B |
| 73 | FTRE Fortrea Holdings Inc. | $2.2B |
| 74 | AUPH Aurinia Pharmaceuticals Inc. | $2.2B |
| 75 | PGEN Precigen, Inc. | $2.2B |
| 76 | AGIO Agios Pharmaceuticals, Inc. | $2.2B |
| 77 | VCEL Vericel Corporation | $2.2B |
| 78 | HRMY Harmony Biosciences Holdings, Inc. | $2.1B |
| 79 | BHVN Biohaven Ltd. | $2.1B |
| 80 | IMNM Immunome, Inc. | $2.0B |
| 81 | VERA Vera Therapeutics, Inc. | $2.0B |
| 82 | ZYME Zymeworks Inc. | $2.0B |
| 83 | RXRX Recursion Pharmaceuticals, Inc. | $2.0B |
| 84 | MRVI Maravai LifeSciences Holdings, Inc. | $1.9B |
| 85 | SEPN Septerna, Inc. | $1.9B |
| 86 | SRPT Sarepta Therapeutics, Inc. | $1.9B |
| 87 | XNCR Xencor, Inc. | $1.9B |
| 88 | MLYS Mineralys Therapeutics, Inc. | $1.8B |
| 89 | PVLA Palvella Therapeutics, Inc. | $1.8B |
| 90 | TRVI Trevi Therapeutics, Inc. | $1.8B |
| 91 | VIR Vir Biotechnology, Inc. | $1.8B |
| 92 | ZBIO Zenas BioPharma, Inc. | $1.8B |
| 93 | MAZE Maze Therapeutics, Inc. | $1.7B |
| 94 | URGN UroGen Pharma Ltd. | $1.7B |
| 95 | KLRA Kailera Therapeutics, Inc. | $1.7B |
| 96 | STOK Stoke Therapeutics, Inc. | $1.6B |
| 97 | NUVB Nuvation Bio Inc. | $1.6B |
| 98 | NVAX Novavax, Inc. | $1.6B |
| 99 | IMCR Immunocore Holdings plc | $1.6B |
| 100 | ABSI Absci Corporation | $1.6B |
| 101 | TRAX First Tracks Biotherapeutics, Inc. | $1.6B |
| 102 | NTLA Intellia Therapeutics, Inc. | $1.6B |
| 103 | RARE Ultragenyx Pharmaceutical Inc. | $1.5B |
| 104 | INVA Innoviva, Inc. | $1.5B |
| 105 | ANAB AnaptysBio, Inc. | $1.4B |
| 106 | OCUL Ocular Therapeutix, Inc. | $1.4B |
| 107 | INBX Inhibrx Biosciences, Inc. | $1.4B |
| 108 | ORIC ORIC Pharmaceuticals, Inc. | $1.4B |
| 109 | DMRA Damora Therapeutics, Inc. | $1.3B |
| 110 | TSHA Taysha Gene Therapies, Inc. | $1.3B |
| 111 | NKTR Nektar Therapeutics | $1.3B |
| 112 | LBRX LB Pharmaceuticals Inc | $1.2B |
| 113 | RAPP Rapport Therapeutics, Inc. | $1.2B |
| 114 | TYRA Tyra Biosciences, Inc. | $1.2B |
| 115 | OMER Omeros Corporation | $1.2B |
| 116 | SNDX Syndax Pharmaceuticals, Inc. | $1.2B |
| 117 | AVLN Avalyn Pharma Inc. | $1.2B |
| 118 | BCAX Bicara Therapeutics Inc. | $1.1B |
| 119 | REPL Replimune Group, Inc. | $1.1B |
| 120 | VOR Vor Biopharma Inc. | $1.1B |
| 121 | AVBP ArriVent BioPharma, Inc. | $1.0B |
| 122 | MNKD MannKind Corporation | $1.0B |
| 123 | JANX Janux Therapeutics, Inc. | $1.0B |
| 124 | JBIO Jade Biosciences, Inc. | $927.9M |
| 125 | GLUE Monte Rosa Therapeutics, Inc. | $924.8M |
| 126 | CGEM Cullinan Therapeutics, Inc. | $924.8M |
| 127 | VSTM Verastem, Inc. | $909.3M |
| 128 | RIGL Rigel Pharmaceuticals, Inc. | $899.1M |
| 129 | CRVS Corvus Pharmaceuticals, Inc. | $885.8M |
| 130 | MGTX MeiraGTx Holdings plc | $884.6M |
| 131 | ALMS Alumis Inc. | $877.6M |
| 132 | AKTS Aktis Oncology, Inc. | $874.9M |
| 133 | SVRA Savara Inc. | $867.0M |
| 134 | ANRO Alto Neuroscience, Inc. | $862.1M |
| 135 | KURA Kura Oncology, Inc. | $854.9M |
| 136 | ABUS Arbutus Biopharma Corporation | $831.0M |
| 137 | FDMT 4D Molecular Therapeutics, Inc. | $779.5M |
| 138 | ARDX Ardelyx, Inc. | $767.5M |
| 139 | ANNX Annexon, Inc. | $766.7M |
| 140 | GERN Geron Corporation | $719.6M |
| 141 | SANA Sana Biotechnology, Inc. | $697.5M |
| 142 | OABI OmniAb, Inc. | $677.5M |
| 143 | DNA Ginkgo Bioworks Holdings, Inc. | $672.7M |
| 144 | ACHV Achieve Life Sciences, Inc. | $667.8M |
| 145 | PRME Prime Medicine, Inc. | $665.7M |
| 146 | AURA Aura Biosciences, Inc. | $653.3M |
| 147 | DSGN Design Therapeutics, Inc. | $640.8M |
| 148 | SLDB Solid Biosciences Inc. | $634.8M |
| 149 | LXRX Lexicon Pharmaceuticals, Inc. | $631.8M |
| 150 | WVE Wave Life Sciences Ltd. | $626.6M |
| 151 | CADL Candel Therapeutics, Inc. | $614.4M |
| 152 | CRMD CorMedix Inc. | $611.9M |
| 153 | SGMT Sagimet Biosciences Inc. | $595.5M |
| 154 | CLYM Climb Bio Inc | $585.3M |
| 155 | IMMX Immix Biopharma, Inc. | $583.0M |
| 156 | ZVRA Zevra Therapeutics, Inc. | $582.6M |
| 157 | DBVT DBV Technologies S.A. | $577.3M |
| 158 | MDXG MiMedx Group, Inc. | $569.9M |
| 159 | OLMA Olema Pharmaceuticals, Inc. | $560.9M |
| 160 | ACRS Aclaris Therapeutics, Inc. | $552.0M |
| 161 | CTMX CytomX Therapeutics, Inc. | $505.5M |
| 162 | ARVN Arvinas, Inc. | $477.3M |
| 163 | MNPR Monopar Therapeutics Inc. | $474.2M |
| 164 | NGNE Neurogene Inc. | $471.3M |
| 165 | PHAT Phathom Pharmaceuticals, Inc. | $464.4M |
| 166 | RGNX REGENXBIO Inc. | $441.0M |
| 167 | ALLO Allogene Therapeutics, Inc. | $431.9M |
| 168 | PRTA Prothena Corporation plc | $421.0M |
| 169 | ALT Altimmune, Inc. | $412.4M |
| 170 | AUTL Autolus Therapeutics plc | $409.9M |
| 171 | SPRY ARS Pharmaceuticals, Inc. | $400.8M |
| 172 | TECX Tectonic Therapeutic, Inc. | $392.4M |
| 173 | CCCC C4 Therapeutics, Inc. | $376.5M |
| 174 | AVTX Avalo Therapeutics, Inc. | $371.7M |
| 175 | MPLT MapLight Therapeutics, Inc. | $369.6M |
| 176 | EDIT Editas Medicine, Inc. | $368.6M |
| 177 | FENC FENNEC PHARMACEUTICALS INC. | $353.5M |
| 178 | RLMD Relmada Therapeutics, Inc. | $348.8M |
| 179 | CAPR Capricor Therapeutics, Inc. | $344.8M |
| 180 | ENTA Enanta Pharmaceuticals, Inc. | $339.0M |
| 181 | KYTX Kyverna Therapeutics, Inc. | $333.3M |
| 182 | AVIR Atea Pharmaceuticals, Inc. | $324.0M |
| 183 | ZURA Zura Bio Ltd | $322.0M |
| 184 | XFOR X4 Pharmaceuticals, Inc | $321.2M |
| 185 | FULC Fulcrum Therapeutics, Inc. | $280.8M |
| 186 | ARCT Arcturus Therapeutics Holdings Inc. | $279.7M |
| 187 | FATE Fate Therapeutics, Inc. | $252.8M |
| 188 | RCKT Rocket Pharmaceuticals, Inc. | $251.4M |
| 189 | OCGN Ocugen, Inc. | $250.8M |
| 190 | LRMR Larimar Therapeutics, Inc. | $244.1M |
| 191 | VNDA Vanda Pharmaceuticals Inc. | $242.5M |
| 192 | DRUG Bright Minds Biosciences Inc. | $237.4M |
| 193 | PALI PALISADE BIO, INC. | $231.8M |
| 194 | LXEO Lexeo Therapeutics, Inc. | $229.7M |
| 195 | KROS Keros Therapeutics, Inc. | $223.7M |
| 196 | IKT Inhibikase Therapeutics, Inc. | $221.9M |
| 197 | ALEC Alector, Inc. | $204.3M |
| 198 | NAGE Niagen Bioscience, Inc. | $192.3M |
| 199 | ADCT ADC Therapeutics SA | $183.8M |
| 200 | KRRO Korro Bio, Inc. | $176.4M |
| 201 | TRDA Entrada Therapeutics, Inc. | $171.7M |
| 202 | SION Sionna Therapeutics, Inc. | $162.8M |
| 203 | CHRS Coherus Oncology, Inc. | $156.0M |
| 204 | MDWD MediWound Ltd. | $154.0M |
| 205 | UPB Upstream Bio, Inc. | $150.1M |
| 206 | RNA Atrium Therapeutics, Inc. | $140.3M |
| 207 | CDXS Codexis, Inc. | $140.2M |
| 208 | CMPX Compass Therapeutics, Inc. | $137.0M |
| 209 | NKTX Nkarta, Inc. | $128.2M |
| 210 | AVXL Anavex Life Sciences Corp. | $123.3M |
| 211 | HUMA Humacyte, Inc. | $121.0M |
| 212 | VYGR Voyager Therapeutics, Inc. | $107.2M |
| 213 | LENZ LENZ Therapeutics, Inc. | $99.3M |
| 214 | HRTX Heron Therapeutics, Inc. | $57.5M |
| 215 | ALDX Aldeyra Therapeutics, Inc. | $39.2M |
| 216 | EYPT EyePoint, Inc. | $34.9M |
| 217 | IRLA Quince Therapeutics, Inc. | $33.6M |
| 218 | ATYR aTyr Pharma, Inc. | $16.2M |
| 219 | SCNI Scinai Immunotherapeutics Ltd. | $3.2M |
Questions
- What are the largest biotechnology stocks?
- By market cap: Vertex Pharmaceuticals Incorporated (VRTX) $132.8B, Regeneron Pharmaceuticals, Inc. (REGN) $82.9B, Moderna, Inc. (MRNA) $79.9B, Revolution Medicines, Inc. (RVMD) $40.1B, Royalty Pharma plc (RPRX) $36.7B, Alnylam Pharmaceuticals, Inc. (ALNY) $30.0B, Roivant Sciences Ltd. (ROIV) $26.4B, Incyte Corporation (INCY) $23.5B, Insmed Incorporated (INSM) $20.4B, Exelixis, Inc. (EXEL) $16.0B.
- How many biotechnology companies are listed in the U.S.?
- EquiReason covers 219 U.S.-listed companies in this industry; the full list is above.
How these figures are read: methodology · EquiReason.